Join host Dhanvin Yajaman on a captivating journey into the world of healthcare and medicine in this episode of "A New Healthcare Era." In this installment, we explore the revolutionary treatment for the reduction of low-density lipoprotein (LDL) cholesterol—Inclisiran.

High levels of LDL cholesterol contribute significantly to cardiovascular disease, but Inclisiran, an injectable small interfering RNA, is changing the game. Unlike traditional statins, Inclisiran requires infrequent dosing (just twice per year) and provides sustained and effective LDL reduction in conjunction with statins. Its prolonged effect holds the potential to address medication noncompliance, a leading cause of failure to lower LDL cholesterol levels.

Delve into the captivating science behind Inclisiran as we uncover its mechanism of action, targeting the PCSK9 protein. Explore the remarkable clinical trials, such as ORION-10, which demonstrated significant LDL reduction and an impressive safety profile. Real-world data will also be discussed, revealing how Inclisiran is already making a positive impact on the lives of patients and transforming the way LDL cholesterol is managed.

Don't miss this enlightening episode that explores the potential of Inclisiran in reshaping the future of LDL cholesterol management. Tune in to "A New Healthcare Era: Reducing LDL with Inclisiran"